Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-676: pembrolizumab plus BCG versus BCG in high-risk non-muscle invasive bladder cancer
2022-501817-29-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 29
01
Overview
Phase 3, randomised trial of pembrolizumab and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC) (4 cohorts), sponsored by Merck & Co. Primary endpoints: Complete Response Rate by Blinded Independent Central Review and Event-Free Survival. Planned start Nov 2018; status: authorised.
02
Drugs
pembrolizumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2022-501817-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501817-29-00.